ERBB2 and breast carcinoma: Dacomitinib also demonstrated inhibition of HER2-amplified trastuzumab and lapatinib resistant breast cancer cell lines in vitro; exerting its antiproliferative effects through a G0- G1 combined cell cycle arrest and inducing apoptosis [71].